{'fraction_non_alphanumeric': 0.04832104832104832, 'fraction_numerical': 0.056511056511056514, 'mean_word_length': 4.9609756097560975, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Comparative Evaluation of Monistat and Mycostatin in the Treatment of Vulvovaginal Candidiasis

Monistat Cream® (5.0 g cream equivalent to 0.1 g miconazole nitrate) and Mycostatin Tablets ® (100,000 units nystatin) were compared in the treatment of 116 pregnant and nonpregnant patients with vulvovaginal candidiasis. Of the 56 patients treated with Monistat, 91.1% (51 patients) were cured. Of the 60 patients treated with Mycostatin, 76.6% (46 patients) were cured. This difference in cure rate was statistically significant (0.05). In the pregnant group, all 23 patients (100%) treated with Monistat and 19 of 23 patients (82.6%) treated with Mycostatin were cured. In the nonpregnant group, 28 of 33 patients (84.8%) treated with Monistat and 27 of 37 patients (73%) treated with Mycostatin were cured. Within the nonpregnant group. Monistat cured 14 of 17 oral contraceptive users (82.4%); Mycostatin cured 12 of 19 (63.2%). Side effects were minimal and comparable in the two treatment groups. One patient on Mycostatin had to discontinue therapy because of drug-related side effects. This study demonstrated the superior therapeutic efficacy of Monistat cream when evaluated with Mycostatin in a comparative study.